Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00549679 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: GSK256066
DRUG: Placebo

Sponsor

GlaxoSmithKline